[go: up one dir, main page]

WO2024236429A2 - Favorisation de la pousse des cheveux - Google Patents

Favorisation de la pousse des cheveux Download PDF

Info

Publication number
WO2024236429A2
WO2024236429A2 PCT/IB2024/054527 IB2024054527W WO2024236429A2 WO 2024236429 A2 WO2024236429 A2 WO 2024236429A2 IB 2024054527 W IB2024054527 W IB 2024054527W WO 2024236429 A2 WO2024236429 A2 WO 2024236429A2
Authority
WO
WIPO (PCT)
Prior art keywords
hair
use according
subject
composition
hair loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/054527
Other languages
English (en)
Other versions
WO2024236429A3 (fr
Inventor
Cornelia PYKO
Feryel ADAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carbocode SA
Carbocode SA
Original Assignee
Carbocode SA
Carbocode SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carbocode SA, Carbocode SA filed Critical Carbocode SA
Publication of WO2024236429A2 publication Critical patent/WO2024236429A2/fr
Publication of WO2024236429A3 publication Critical patent/WO2024236429A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides

Definitions

  • the present invention relates to a use of a composition for promoting hair growth or for preventing hair loss on skin of a subject.
  • Hair is a filamentous biomaterial, which grows on human scalp approximately 0.3 mm/day, while it sheds 100 hairs/day. Hair often refers to two structures: the part beneath the skin, i.e. the hair bulb, and the hair shaft which is the hard filamentous part extending above the skin surface. Hair affects the impacts of thermoregulation, physical protection and social interaction. In humans, the main function of hair is an important facet of appearance. Hair loss or alopecia is defined as the loss of hair from an area of the body. Hair loss or slowed hair growth affects millions of people, including over 40% of men over the age of 30 and a significant number of women also. Factors responsible for hair loss include scarring, disease, infection, less blood circulation in the blood capillaries of scalp and androgen sensitivity.
  • hair growth is the result of the growth and differentiation of hair follicles comprising dermal papilla cells and epithelial cells. Hair follicle stem cells sustain growth and cycling of the hair follicle and are located in the permanent portion of the follicle known as the bulge. Cyclical changes in hair follicle growth are divided into different stages, referred to as anagen (growth), catagen (regression), telogen (rest), and exogen (shedding). The human hair cycle transition is controlled by several growth stimulatory or inhibitory factors.
  • the duration of each stage varies depending on the type, site, and genetic programming of the follicle. Often, the growth phases of the hair shorten with increasing age, leading to the formation of shorter and/or finer hair. Shifting the ratio of actively growing hair to hair in the resting phase can lead to reduced hair density. In the extreme case, hair growth cycle comes to a complete stop, resulting in baldness.
  • Drug-based therapies for the treatment of hair loss are available, but they have shown various side effects in patients. Thus, the use of new approaches using bioactive products to promote hair growth have been emphasized.
  • a number of compounds have been described in order to reduce the visible effects of alopecia. Some substances can prevent or reduce the loss of hair. Other substances can promote hair growth, particularly by promoting the hair follicles and as a result initiating a new hair growth cycle.
  • Ceramide NG efficiently promotes hair growth or reduces hair loss on skin of a subject. Ceramide NG is especially targeted at extending the anagen growth phase of the hair cycle and activating the hair follicle stem cells.
  • the present invention comprises the following aspects:
  • R 1 is an alkyl chain having 10 - 20 carbon atoms
  • R 2 is an acyl having 16-34 carbon atoms
  • X is hydrogen, a glucosyl moiety or a lactosyl moiety, for promoting hair growth or for preventing hair loss on skin of a subject.
  • composition comprising a compound of formula I.
  • the composition is a topical composition and used for cosmetic purposes on the scalp and/or the hair of a human, i.e. a cosmetic hair composition, or on the hair or fur of a domestic animal.
  • Figure 1 shows a heatmap using a log2 scale with upregulation (shown in black) or downregulation (shown in white) of respective proteins upon treatment with 0.01 % (01), 0.03 % (03) and 0.15 % (15) of ceramide NG in vehicle as compared to vehicle without ceramide (VEH); detailed experimental setup explained in Example 1.
  • the present invention relates to a use of a composition for promoting hair growth or for preventing hair loss on skin of a subject, wherein the composition comprises a compound of formula I
  • R 1 is an alkyl chain having 10 - 20 carbon atoms
  • R 2 is an acyl chain having 16-34 carbon atoms
  • X is hydrogen, a glucosyl moiety or a lactosyl moiety.
  • alkyl refers to an acyclic straight hydrocarbyl group in which the carbon atoms may be saturated or contain one or more double and/or triple bonds (so, forming for example an alkenyl or an alkynyl).
  • alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, n-pentyl, neo-pentyl, n-hexyl, ethenyl, propenyl, 1-butenyl, 2-butenyl, isobutenyl,l-pentenyl, 2- pentenyl, 2-methyl-l-butenyl, 3-methyl-l-butenyl, 2-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3 -hexenyl, methylpentenyl, dimethylbutenyl, ethynyl, propynyl, 1-butynyl, 2-butynyl, pentynyl, and hexynyl.
  • compositions suitable for topical application on keratinous tissue includes keratin-containing layers disposed as the outermost protective covering of mammals and includes herein especially skin, scalp and hair.
  • Topical compositions are typically dermatologically acceptable in that they do not have undue toxicity, incompatibility, instability, allergic response, and the like, when applied to skin.
  • composition of the present invention is especially intended for cosmetic purposes on the scalp and scalp hair of a human and is preferably a cosmetic hair composition, or on the hair or fur of a domestic animal such as a dog, a cat or a horse.
  • Hair is defined as a stratified squamous keratinized epithelium made of multi-layered flat cells whose rope-like filaments provide structure and strength to the hair shaft. Hair as used herein refers to both hair on the scalp of a human or to hair on the body of an animal, where it can be used herein interchangeably with “fur”.
  • subject refers to a mammal having hair.
  • the subject is a human.
  • the human is in some embodiments a man. Men are more often affected by hair loss compared to women. They often suffer from a gender-specific form of hair loss, so-called androgenetic or androgenic alopecia. This form of hair loss is hereditary and often arises at young age. The main cause of this form of hair loss is the steroid hormone dihydrotestosterone (DHT). It is formed in the human body by the enzyme steroid-5-alpha-reductase from the male sex hormone testosterone and, in the event of inherited DHT hypersensitivity, leads to the shortening of the anagen phase of the hair.
  • DHT dihydrotestosterone
  • hair loss refers to locally limited, circular hair loss.
  • This form of hair loss is an inflammatory autoimmune disease caused by lymphocytes that attack the bulb of hair follicles in the anagen phase, and it can occur at any stage.
  • the human is in other embodiments a woman.
  • One form of hair loss which is primarily observed in women is diffuse alopecia
  • Diffuse alopecia manifests in a time-limited loss of hair, the possible causes being diverse, e.g. hormone fluctuations, stress or lack of iron.
  • Factors causing hair loss in humans include especially a reduction in hair follicle function due to male hormones, reduction in metabolic functions of hair follicles and hair bulbs, reduction in scalp physiological functions and local impairment of the circulation due to tension in the scalp.
  • the subject is a domestic animal. Included are e.g. dogs, cats, horses, sheep, rabbits and hamsters. Preferred domestic animals include dogs, cats and horses.
  • hair of domestic animals basically has the same hair cycle stages as in humans, there are still several differences between human hair and of domestic animals. For example, humans grow singular hairs which continuously grow, whereas dog’s fur grows in bundles within each follicle, growing and shedding in cycles that differ by breed and depend on season and temperature. These bundles consist of a primary outer coat which can be coarse and a secondary soft undercoat. Moreover, the core of the hair follicle allows for the coating of hair to provide insulation from heat, cold and rain.
  • Alopecia may e g. show as bald circles on parts of the animal fur.
  • Domestic animals may acquire alopecia e.g. from a parasitic infestation of fleas, lice, mosquitoes, inadequate diet, food allergies, fungal or bacterial infections.
  • Endocrine diseases such as hypothyroidism, cushing’s disease, or reactions to rabies and corticosteroid injections can also cause alopecia.
  • Other forms of alopecia known in dogs include e.g. seasonal flank alopecia, showing up during the cold winter months on both sides of the abdomen in front of the rear legs, or alopecia X.
  • Treating or any variation of the term such as treating means to address a condition with the objective of improving or stabilising an outcome in the subject being treated or addressing an underlying need. Treating therefore includes the management of the condition or dermatological needs of the subject being treated. Treating can include cosmetic or medical treatment. Treatment can include preventive or curative treatment. Preventive treatment can include primary prevention or secondary prevention.
  • the compound of formula I may be obtained by any technique known to the skilled person.
  • the sphingoid base moiety may e g. be produced by a fermentation process, such as e.g. described in Schaffer, S. et al; Metabolic Engineering (2012) 14:412-426, or by a chemical process, such as e.g. described in WO 00/68238 or in He, Linli et al; Journal of Organic Chemistry (2000) 65(22):7618-7626.
  • the sphingoid base may then be acylated by any known technique, e.g. enzymatically by the use of lipases, or chemically as e.g. described in WO 2013038985 or in Drug. Del. Sci. Tech. 2014, 24, 689-693, Org. Process Res. Dev. 2019, 23, 452-461.
  • R 1 of the compound of formula I is -C12H25.
  • R 2 of the compound of formula I is an unsubstituted acyl group. More preferably, R 2 of the compound of formula l is a saturated fatty acyl group or a fatty acyl group having one or more double bonds, including especially hexadecanoyl, 2- hydroxyhexadecanoyl, octadecanoyl, 2-hydroxyoctadecanoyl, eicosanoyl, 2- hydroxyeicosanoyl, lignoceroyl, 2-hydroxytetracosanoyl and 30-(linoleyloxy)-triacontanoyl. Even more preferably, R 2 of the compound of formula I is an unsubstituted acyl group having 18-26 carbon atoms
  • R 1 of the compound of formula I is -C12H25 and R 2 is octadecanoyl.
  • X of the compound of formula I is hydrogen.
  • ceramide NG also termed herein as Cer NG or CNG
  • Cer NG Cer NG
  • CNG Cer NG
  • Ceramides as used herein are named according to the shorthand nomenclature developed by Motta et al., Biochim Biophys Acta., 1993, 1182:147-151 and expanded by Rabionet et al., Biochim Biophys Acta, 2014, 1841 :422-434, and by Masukawa et al., Journal of Lipid Research, 2008, 49, 1466-1476.
  • the number of carbons and unsaturations may be expressed in parentheses following the letters of N, A, E, and O.
  • the carbon chain length of the sphingoid base moiety of the ceramides mentioned herein is typically Cis.
  • the carbon chain length of the acyl moiety of the ceramides mentioned herein may be e.g. Ci6, C17, Cis, C19, C20, C22, C24, C 2 s, C28, C30, C32 or C34.
  • Cer NG refers to a ceramide comprising a non-hydroxy acid as acyl moiety and dihydrosphingosine as sphingoid base moiety. Typically, both carbon chain lengths are Cis. Ceramide NG may also be referred to as ceramide NdS and can be used herein interchangeably. Dihydrosphingosine may also be referred to as sphinganine and can be used herein interchangeably.
  • compositions of the present invention will contain from about 0.0001 % to about 10% wt/wt of a compound of formula I, such as from about 0.005 % to about 5% wt/wt of a compound of formula I, or from 0.05 % to about 0.2 % wt/wt, from 0.01 % to about 1% wt/wt of a compound of formula I.
  • the topical compositions of the present invention may contain from about 0.0001 to about 0.00025 % wt/wt of a compound of formula I, from about 0.0002 to about 0.0004 % wt/wt of a compound of formula I, from about 0.0003 to about 0.0005 % wt/wt of a compound of formula I, from about 0.0004 to about 0.0006 % wt/wt of a compound of formula I, from about 0.0005 to about 0.0008 % wt/wt of a compound of formula I, from about 0.0007 to about 0.001 % wt/wt of a compound of formula I, from about 0.001 to about 0.005 % wt/wt of a compound of formula I, from about 0.003 to about 0.008 % wt/wt of a compound of formula I, from about 0.005 to about 0.01 % wt/wt of a compound of formula I, from about 0 008 to
  • topical compositions of the present invention contain an amount of about 0.01 % to 5% wt/wt of a compound of formula I, or an amount of about 0.02 % wt/wt to 1% wt/wt of a compound of formula I. Examples are 0.05 % wt/wt, 0.1 % wt/wt or 0.2 % wt/wt of a compound of formula I.
  • composition may in some embodiments comprise more than one compound of formula I, also termed herein as blend of compounds of formula I.
  • each compound of formula I may be present in the same amount or in different amounts.
  • the ranges or amounts as listed above may relate to the total content of the blend in the composition, or to the amount of one compound in the blend in the composition.
  • composition according to the present invention may also include additional ingredients typically found in hair care formulations and may be selected with regard to their function.
  • additional ingredients typically found in hair care formulations and may be selected with regard to their function.
  • surfactants including cationic, anionic, amphoteric, zwitterionic and ionic surfactants, etc.
  • solvents like water or alcohols
  • solubilizers like ethanol, ethylene glycol, propylene glycol, etc.
  • moisture retainers like glycerin, trehalose, sorbitol, maltitol, dipropylene glycol, 1,3-butylene glycol, sodium hyaluronate, etc.
  • antioxidants like tocopherol, BHT, etc.
  • UV absorbants like benzophenone derivatives, paraamino benzoate derivatives, methoxy cinnamate derivatives, etc.
  • UV-scattering agents like inorganic compounds such as zinc oxide, zirconium oxide, titanium oxide, etc., thick
  • composition of the present invention may be formulated as a leave-on or a rinse-off composition, preferably as a rinse-off composition.
  • “Leave-on compositions” refer to compositions to be applied, typically after hair wash, and allowed to remain on the keratinous tissue, such as the hair and the scalp. These leave-on compositions are to be distinguished from rinse-off compositions, which are applied to the hair or the scalp/skin, either before or after the washing, and subsequently (typically a few minutes) removed either by washing, rinsing, wiping, or the like.
  • Non-limiting examples for rinse-off formulations include shampoo, conditioner, pre- or post-shampooing serum.
  • Non-limiting examples for leave-on formulations include hair tonic, foam or cream.
  • the formulation may be any type of formulation, such as a solid, semi-solid, liquid or emulsion. It may also depend on the subject that it is intended to be applied on. For example, for humans or dogs liquid shampoos are typical, whereas horses or cats may rather be treated with semisolid or emulsion formulations, like cream formulations.
  • the cosmetic compositions according to the invention are hair cleansing compositions such as shampoos, they comprise additionally surfactants such as anionic, nonionic, cationic or amphoteric surfactants.
  • the anionic surfactant may include C8-C24 alkyl sulfate, C8-C24 alkyl ether sulfate, CBC&4 alkyl benzene sulfonate, C8-C&& alkyl phosphate, C8-C&4 polyoxyalkylenealkyl ether phosphate, C8-C24 alkyl sulfosuccinate, C8-C24 polyoxyalkylenealkyl ether sulfosuccinate, Cs-Cz4 acyl alaninate, C8-C Threadacyl N-methyl-[beta]-alaninate, C—C74 acyl glutamate, C8-C&4 acyl isethionate, C8-C&4 acyl sarcosinate, C8-C cramp taurinate, C8-C&4 acyl melO thyl taurinate, [alpha]-sulfofatty acid ester salt, ether carbon
  • the nonionic surfactant may include alkanol amide, glycerin fatty acid ester, polyoxyl5 alkylenealkyl ether, polyoxyalkyleneglycol ether, polyoxyalkylenesorbitan fatty acid ester, sorbitan fatty acid ester, polyoxyalkylenesorbit fatty acid ester, sorbit fatty acid ester, polyoxyalkyleneglycerin fatty acid ester, polyoxyalkylene fatty acid ester, polyoxyalkylenealkylphenyl ether, tetrapolyoxyalkylene ethylenediamine-condensed substances, sucrose fatty acid ester, polyoxyalkylene fatty acid amide, polyoxy20 alkyleneglycol fatty acid ester, polyoxyalkylene castor oil denvatives, polyoxyalkylenehardened castor oil derivatives, or alkylpolyglycoside, polyglycerin fatty acid ester.
  • the amphoteric surfactant may include C8-C24 alkyl amidopropylbetaine, C8-C24 alkyl carboxybetaine, C8-C-4 alkyl sulfobetaine, C8-C-4 alkyl sulfobetaine, C8-C-4 alkyl hy25 droxysulfobetaine, C8-C24 alkyl amidopropylhydroxysulfobetaine, C8-C24 alkyl hydroxyphosphobetaine, C8-C&4 alkyl aminocarboxylate, C8-C24 alkyl imidazoliumbetaine, C8-C74 alkyl amineoxide, C8-C24 alkyl phosphate or esters containing a tertiary or quaternary nitrogen group, wherein C,-C cognitive infrastructure, wherein C,-C cognitive infrastructure, or the like.
  • the cationic surfactants may include alkyltrimethyl ammonium salts, dialkyldimethyl ammonium salts, alkylpyridium salts, alkyldimethylbenzyl ammonium salts, benzethonium chloride or benzalkonium chloride.
  • cosmetic compositions according to the invention are hair conditioning compositions such as hair conditioners, they may comprise additionally further conditioning agents.
  • the conditioning effect may be enhanced e g. by adding silicone (methylpolysiloxane, 10 methylphenyl siloxane, high polymeric methylpolysiloxane, cyclic polysiloxane, polyether- modified silicone, amino-modified silicone, etd.) to a hair treatment composition or skin care composition of the present invention.
  • silicone methylpolysiloxane, 10 methylphenyl siloxane, high polymeric methylpolysiloxane, cyclic polysiloxane, polyether- modified silicone, amino-modified silicone, etd.
  • the composition may advantageously comprise one or more further active ingredients for promoting hair growth or for preventing hair loss.
  • further active ingredients include e.g. various vitamins, in particular vitamins of the B series, e g. vitamin B7 or biotin, amino acids, in particular L-valine or L-arginine, and amino acid derivatives, e.g. creatine or L-carnitine, which, inter alia, stimulate the cell metabolism, caffeine which stimulates blood flow through the scalp and indirectly hair growth, or a plant extract.
  • the composition may comprise one or more further active ingredients for improving hair and scalp care and/or for strengthening damaged hair.
  • composition according to the present invention preferably comprises at least one cosmetically acceptable carrier.
  • cosmetically acceptable means a composition or an agent, which is non-toxic and physiologically acceptable and has optionally further a pleasant appearance, odour, feel and/or taste.
  • the carrier component is selected from water, water-miscible organic solvents, preferably C2-C4-alkanols, in particular ethanol, oils, fats, waxes, esters of C6-C30-monocarboxylic acids with mono-, di- or trihydric alcohols, saturated acyclic and cyclic hydrocarbons, fatty acids, fatty alcohols, propellant gases and mixtures thereof.
  • the cosmetic compositions of the present invention may further comprise substances generally known to be comprised in cosmetic compositions for their multifunctional properties with regard to cosmetic and/or formulating effects, such as amino acids (alginin, glutamic acid, etc.), higher alcohols, higher fatty acids like lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid, oleic acid, undecylenic acid, tall oil fatty acid, coconut oil fatty acid, palm oil fatty acid, palm kernel fatty acid, linolic acid, linoleic acid, eicosapentaenoic acid, docosahexanoic acid, etc.
  • amino acids alginin, glutamic acid, etc.
  • higher alcohols higher fatty acids like lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid, oleic acid, undecylenic acid, tall oil fatty acid,
  • perfumes and fragrances may be added, the smell or odour of the cosmetic formulation to be applied matters.
  • Perfume oils which may be mentioned are mixtures of natural and synthetic fragrances. Natural fragrances are extracts from flowers (lily, lavender, rose, j asmine, neroli, ylang ylang), stems and leaves (geranium, patchouli, petitgrain), fruits (anise, coriander, caraway juniper), fruit peels (bergamot, lemon, oranges), roots (mace, angelica, celery, cardamom, costus, iris, calmus), woods (pinewood, sandalwood, guaiacwood, cedarwood, rosewood), herbs and grasses (tarragon, lemongrass, sage, thyme), needles and branches (spruce, fir, pine, dwarf-pine), resins and balsams (galbanum, elemi, benzoin, myrrh, olibanum, opopon
  • Typical synthetic fragrance compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon types. Fragrance compounds of the ester type are e.g.
  • the ethers include, for example, benzyl ethyl ether; the aldehydes include e g.
  • the linear alkanals having 8 to 18 carbon atoms citral, citronellal, citronellyloxyacetaldehyde, cyclamenaldehyde, hydroxycitronellal, lilial and bourgeonal
  • the ketones include e.g. the ionones, isomethylionone and methyl cedryl ketone
  • the alcohols include anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and terpineol
  • the hydrocarbons include primarily the terpenes and balsams.
  • fragrance oils which are mostly used as aroma components, are also suitable as perfume oils, e.g. sage oil, chamomile oil, clove oil, melissa oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, olibanum oil, galbanum oil, labolanum oil and lavandine oil.
  • Suitable aromas are, for example, peppermint oil, spearmint oil, anise oils, star anise oil, caraway oil, eucalyptus oil, fennel oil, lemon oil, wintergreen oil, clove oil, menthol and the like.
  • Cer NG in the context of the invention it has been found that application of Cer NG on keratinocytes leads to an up-regulation of biomarkers associated with the hair cycle. More precisely, the application of Cer NG leads to up-regulation of ceramide synthase 4, keratin type I cytoskeletal 17 (also referred to herein as Keratin 17) and NAD-dependent protein deacetylase sirtuin-2 (also being referred to herein as Sirtuin-2).
  • Cer NS is used for up-regulating NAD-dependent protein deacetylase sirtuin-2.
  • Cer NG is used for up-regulating ceramide synthase 4.
  • Cer NS is used for up-regulating keratin type I cytoskeletal 17.
  • the hair follows a specific growth cycle in which the anagen phase represents the period of active growth, the longer the anagen phase is the longer and thicker the hair. If the cycle is shortened, which is the case during ageing and stress hair becomes thinner. If premature hair enters the telogen phase it can cause hair loss. Hair thinning and loss are generally attributable to human follicle stem cell reservoir depletion, functional decline, and extended dormancy. Numerous transcription factors, including Sox9, Tbxl, Lhx2, TCF3/4, Foxcl and Nfatcl, help maintain a quiescent and undifferentiated human follicle stem cell status. NFATcl is essential for human follicle stem cell quiescence.
  • Keratin 17 triggers TNF -alpha which is known to activate the hair cycle.
  • Ceramide synthase 4 plays an important role in the maintenance of epidermal stem cell homeostasis and regulation of the hair cycle by regulating bone morphogenetic protein (BMP) and WNT signaling.
  • BMP bone morphogenetic protein
  • Cer NG can activate the hair cycle and therefore promote hair growth.
  • compositions in general are intended a subject who is a mammal.
  • the subject is a human.
  • the human subject is an adult subject, e.g. a human of 20+ years old, especially 30+ years old, such as 40+ years old or 50+ years old.
  • the subject may in some embodiments have an exposure to stress.
  • the exposure may be before the use of the composition of the invention, during the use of the composition of the invention and/or in the planned future relative to the use of the composition of the invention.
  • the skilled person will understand that the term exposure typically relates to a prolonged exposure, such as for a year or many years.
  • the stress may be a psychological stress or an environmental stress.
  • PM particulate matter
  • UV ultraviolet
  • PAH polycyclic aromatic hydrocarbons
  • VOCs volatile organic compounds
  • ozone nitrogen and sulphur oxides
  • particulate matter PM2.5 blue light, ozone, or tobacco smoke.
  • PM10 coarse particles
  • PM2.5 fine particles
  • PM0.1 ultra-fine particles
  • composition of the present invention may be advantageously administered to a subject for at least 7 days, such as for at least 14 days or for at least 21 days.
  • the composition is administered for at least 28 days.
  • composition of the present invention may be administered one time or several times per day, such as 2-3 times per day. Typically, the composition is administered for consecutive days.
  • R 1 is an alkyl chain having 10 - 20 carbon atoms
  • R 2 is an acyl having 16-34 carbon atoms
  • X is hydrogen, a glucosyl moiety or a lactosyl moiety, for promoting hair growth or for preventing hair loss on skin of a subject.
  • R 1 of the compound of formula I is -C13H27 and/or R 2 is an acyl having 18-26 carbon atoms.
  • any one of embodiments 1 to 3 comprising an increase of expression levels of one or more biomarkers associated with the subject’s hair cycle, preferably ceramide synthase 4, keratin type I cytoskeletal 17 and/or NAD-dependent protein deacetylase sirtuin-2.
  • promoting hair growth or preventing hair loss on skin of a subj ect comprises activation of the subj ect’ s hair cycle, extension of anagen growth phase of the hair cycle and/or activation of hair follicle stem cells of the subject.
  • composition further comprises a ceramide, such as ceramide NP or ceramide NS, a glycosylated ceramide, such as lactosyl ceramide or glucosyl ceramide, a sphingolipid, such as sphinganine, phytosphingosine or sphingosine, or a combination thereof.
  • a ceramide such as ceramide NP or ceramide NS
  • a glycosylated ceramide such as lactosyl ceramide or glucosyl ceramide
  • a sphingolipid such as sphinganine, phytosphingosine or sphingosine, or a combination thereof.
  • composition comprises a further agent for promoting hair growth or for preventing hair loss, such as gingko biloba, aloe, asiasari, proanthocyanidin, arginine, castor oil, minoxidil, taurine, caffeine, carnitine, azelaic acid, hydrolyzed keratin, biotin, creatine, niacin, panthenol, ximenynic acid, arjunolic acid, vitamin B6, zinc, copper, magnesium, ginseng, or a combination thereof.
  • a further agent for promoting hair growth or for preventing hair loss such as gingko biloba, aloe, asiasari, proanthocyanidin, arginine, castor oil, minoxidil, taurine, caffeine, carnitine, azelaic acid, hydrolyzed keratin, biotin, creatine, niacin, panthenol, ximenynic acid, arjunolic acid, vitamin B6, zinc, copper
  • compositions are administered to a subject for at least 2 days, especially for at least 7 days or for at least 14 days, such as for 28 days.
  • composition is a cosmetic composition.
  • composition is formulated as a shampoo, tonic, hair conditioner, pre- or post-shampooing serum, foam or cream.
  • R 1 is an alkyl chain having 10 - 20 carbon atoms
  • R 2 is an acyl having 16-34 carbon atoms
  • X is hydrogen, a glucosyl moiety or a lactosyl moiety; or a composition as defined in any of embodiments 1-17.
  • Method for activating a hair cycle on skin of a subject comprising administering to the skin a composition comprising a compound of formula I wherein
  • R 1 is an alkyl chain having 10 - 20 carbon atoms
  • R 2 is an acyl having 16-34 carbon atoms
  • X is hydrogen, a glucosyl moiety or a lactosyl moiety; or a composition as defined in any of embodiments 1-17.
  • Example 1 Characterisation of effect of ceramide NG as cosmetic active ingredient
  • RHE Reconstructed Human Epidermis
  • This system mimics the in vivo 3D structure of epidermal tissue as well as the conditions and processes that occur in normal epidermis.
  • RHE are cultured using the medium provided by the manufacturer until analysis.
  • RHE are maintained in survival for 24 hours, before RHE are topically treated with the respective ceramide in a base emulsion for 24h.
  • 3 RHE are treated with base emulsion alone and 3 more remained untreated as a control batch (Ctrl).
  • RHE are incubated under classical cell culture conditions (37°C, 5% CO2).
  • Protein is extracted using the Pierce Total Protein Extraction Kit (Thermo Fisher) according to manufacturer’s recommendations.
  • the protein is mixed with Laemmli buffer and heated to 37°C for 30 min. Protein concentration is determined by the BCA method and standardized for all samples.
  • the samples are separated by SDS PAGE and digested with trypsin overnight.
  • the peptides generated are acidified and separated.
  • the mass spectra are queried using Proteome Discoverer (version 2.5).
  • the resulting MS/MS data are queried against the Homo sapiens proteome UP000005640 (20371 reviewed entries). Results are filtered based on unique peptides >2, and global peptide scores. Analyses are performed using Proteome Discoverer 2.5 to check for overall sample quality.
  • Bioinformatics and statistical analysis Proteomic analysis returned a mean total of 34961 high- quality peptides corresponding to a mean 2422 identifiable and quantifiable RHE proteins among conditions. Proteins with a p-value ⁇ 0.05 in at least one of the concentrations tested for a lipid are considered significant and used for pairwise comparisons. Relevant proteins are classified by their biological processes and associated pathways using the publicly available gene ontology (GO) database provided by the Gene Ontology Consortium and Reactome. Interactome analysis was performed using Cytoscape combined with STRING.
  • GO gene ontology
  • Example 2 Effect of Cer NG on hair growth in human scalp on skin explants
  • Cer NG is topically applied to 4x6 mm scalp skin fragments at three different concentrations. One vehicle is applied as control.
  • the evaluated parameters include hair shaft elongation using Brightfield microscopy, skin morphology and integrity using H&E staining, hair matrix keratinocyte proliferation and apoptosis (Ki-67/Tunel immunostaining), hair cycle staging using Ki-67/Tunel immunostaining and Masson Fontana histochemistry), and number and proliferation of bulge stem cells by K15/Ki-67 immunostaining.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'une composition comprenant un composé de formule I, dans laquelle R1 est une chaîne alkyle ayant 10 à 20 atomes de carbone, R2 est un acyle ayant 16 à 34 atomes de carbone, X est un hydrogène, une fraction glucosyle ou une fraction lactosyle pour favoriser la pousse des cheveux ou pour empêcher la chute des cheveux sur la peau d'un sujet.
PCT/IB2024/054527 2023-05-12 2024-05-09 Favorisation de la pousse des cheveux Pending WO2024236429A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT118648 2023-05-12
PT11864823 2023-05-12

Publications (2)

Publication Number Publication Date
WO2024236429A2 true WO2024236429A2 (fr) 2024-11-21
WO2024236429A3 WO2024236429A3 (fr) 2025-03-20

Family

ID=91580765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/054527 Pending WO2024236429A2 (fr) 2023-05-12 2024-05-09 Favorisation de la pousse des cheveux

Country Status (1)

Country Link
WO (1) WO2024236429A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068238A1 (fr) 1999-05-10 2000-11-16 Lipiderm Ltd. Procede de preparation a grande echelle de sphingosines et de ceramides
WO2013038985A1 (fr) 2011-09-13 2013-03-21 花王株式会社 Procédé de fabrication d'un n-acylamino triol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63255213A (ja) * 1987-04-13 1988-10-21 Kanebo Ltd 養毛化粧料

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068238A1 (fr) 1999-05-10 2000-11-16 Lipiderm Ltd. Procede de preparation a grande echelle de sphingosines et de ceramides
WO2013038985A1 (fr) 2011-09-13 2013-03-21 花王株式会社 Procédé de fabrication d'un n-acylamino triol

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DRUG. DEL. SCI. TECH., vol. 24, 2014, pages 689 - 693
HE, LINLI ET AL., JOURNAL OF ORGANIC CHEMISTRY, vol. 65, no. 22, 2000, pages 7618 - 7626
MASUKAWA ET AL., JOURNAL OF LIPID RESEARCH, vol. 49, 2008, pages 1466 - 1476
MOTTA ET AL., BIOCHIM BIOPHYS ACTA, vol. 1182, 1993, pages 147 - 151
ORG. PROCESS RES. DEV., vol. 23, 2019, pages 452 - 461
RABIONET ET AL., BIOCHIM BIOPHYS ACTA, vol. 1841, 2014, pages 422 - 434
SCHAFFER, S ET AL., METABOLIC ENGINEERING, vol. 14, 2012, pages 412 - 426

Also Published As

Publication number Publication date
WO2024236429A3 (fr) 2025-03-20

Similar Documents

Publication Publication Date Title
JP6896689B2 (ja) 水棲動物軟骨抽出物
US20120220541A1 (en) Use of yeast peptide hydrolysate as an active agent for strengthening hair
JP6788966B2 (ja) 化粧料
JP7426117B2 (ja) 抗皮膚老化剤
EP3429696B1 (fr) Hydrolysat peptidique et osidique des fèves de cacao, compositions cosmetiques le comprenant et leurs utilisations cosmétiques
JP7135106B2 (ja) 頭皮頭髪用組成物
JP2009191039A (ja) ヒアルロン酸合成酵素３ｍＲＮＡ発現促進剤、アクアポリン３ｍＲＮＡ発現促進剤、セリンパルミトイルトランスフェラーゼｍＲＮＡ発現促進剤及びラミニン５産生促進剤
JP2010254667A (ja) コラーゲンゲル収縮剤
WO2024236429A2 (fr) Favorisation de la pousse des cheveux
JP2020138932A (ja) Ａｂｃａ１２遺伝子発現促進剤
CN114206363B (zh) 用于促进头发生长的水飞蓟瘦果提取物
JP5878751B2 (ja) 毛髪化粧料
CN121175025A (zh) 促进毛发生长
KR20100024322A (ko) 탈모방지 및 양모효과가 있는 샴푸 조성물
JP6039271B2 (ja) キューティクル細胞分化促進剤
JP2007031418A (ja) 発毛を促進する方法
JP2012219031A (ja) ラミニン５産生促進剤、インテグリンα６β４産生促進剤、皮膚基底膜正常化剤、皮膚損傷回復促進剤及びアクアポリン３ｍＲＮＡ発現促進剤
JP7766360B2 (ja) フィラグリン ｍＲＮＡ発現促進剤
JP2002284648A (ja) 育毛剤組成物
JP2012121856A (ja) Ｖｅｇｆ産生促進剤、ｉｇｆ−１産生促進剤、ｈｇｆ産生促進剤、及びｂｍｐ−２産生促進剤
JP2011051967A (ja) コラーゲンゲル収縮剤
KR20190020539A (ko) 밤송이 유래 신규 화합물을 포함하는 탈모 개선용 조성물
JP2008530181A (ja) 少なくとも１種類の天然Ａｃ−Ｎ−Ｓｅｒ−Ａｓｐ−Ｌｙｓ−Ｐｒｏテトラペプチドまたはその類似体の１つの、毛髪喪失を遅延させ、かつ／または毛髪成長を刺激するための薬剤としての化粧料的使用
JP2000178128A (ja) 肌とこころの化粧料
JP7236755B2 (ja) 育毛用組成物、遺伝子の発現促進用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24733288

Country of ref document: EP

Kind code of ref document: A2